FindTrial
Sign In

Study on Risk Factor Analysis of New-Onset Diabetes after Liver Transplantation and Significance of Interleukin-6 (IL6) Running Head: new-onset diabetes after liver transplantation

Study on Risk Factor Analysis of New-Onset Diabetes after Liver Transplantation and Significance of Interleukin-6 (IL6) Running Head: new-onset diabetes after liver transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047004
Enrollment
Unknown
Registered
2021-06-06
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

New-onset diabetes mellitus after liver transplantation

Interventions

case series:N/A

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients received liver transplantation in our hospital on September 2013 to October 2020 were selected.

Exclusion criteria

Exclusion criteria: 1. Died within 24 hours after surgery; 2. Suffered from diabetes before the operation; 3. Patients who were followed up in our department after transplantation in other transplant centers; 4. Age less than 18 years old; 5. Autologous liver transplantation; 6. Multi-organ joint transplantation; 7. The follow-up time is less than 6 months.

Design outcomes

Primary

MeasureTime frame
Blood glucose;—

Secondary

MeasureTime frame
Interleukin-6;liver function;Hospitalization;Follow-up time;Operative parameters;—

Countries

China

Contacts

Public ContactHe Yibiao

The First Affiliated Hospital of Xinjiang Medical University

zixiu123@sina.com+86 13899881677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026